GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo targets hard-to-treat stomach cancer spread
Disease control Recruiting nowThis study tests a combination of drugs (LM-302, S-1, and intraperitoneal paclitaxel) with or without another drug (cadonilimab) in people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The goal is to see if t…
Matched conditions: GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
New drug combo aims to shrink stomach tumors before surgery
Disease control Recruiting nowThis study tests two drug combinations given before surgery for people with a specific type of advanced stomach or gastroesophageal junction cancer that has a protein called claudin 18.2. About 88 participants will receive either tislelizumab plus LM-302 and S-1, or tislelizumab …
Matched conditions: GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 18, 2026 12:02 UTC